- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
Veta Health Announces New Partnerships
The virtual health and remote care company is partnering with BioIntelliSense and Stel Life.
Veta Health is teaming up with multiple companies to improve its device portfolio and clinical workflows. The company also announced a new hub for its AI-enabled virtual care solution.
BioIntelliSense, a health monitoring and clinical intelligence company, will provide its line of BioButton wearable devices for Veta Health’s platform. Meanwhile, Stel Life will provide services to Veta Health to help provide a cellular connection option to more devices on the platform.
In a press release, Veta Health CEO James Sutcliffe said, “Our strategic partnerships with BioIntelliSense and Stel Life will play a pivotal role in diversifying our cellular-enabled device offerings, ensuring that healthcare providers have access to ground-breaking technology to deliver the best possible care to their patients. Prosper represents a significant step forward in delivering more accessible and integrated healthcare solutions."
Veta Health announced that Prosper, an AI-enabled virtual care platform, will be available for download on Epic’s Connection Hub.
What Pharma Fears Most About AI
October 4th 2023In this Q&A with Pharmaceutical Executive®, Andrew Hopkins, founder and CEO of Exscientia, reveals how artificial intelligence (AI) is currently being utilized in the pharma industry, predictions for where AI can be implemented in the future, and what pharma fears most about AI.
